Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites

  • 237 Accesses

  • 93 Citations

Abstract

Previous studies have shown that ferrochloroquine (FQ) exhibited an antimalarial activity against Plasmodium spp. The present work confirmed this activity, described the curative effect on P. vinckei and investigated the FQ toxicity in vitro and in vivo. The in vitro and in vivo growth inhibition of P. falciparum and P. berghei N, respectively, showed that FQ antimalarial activity was 1.5–10 times more potent than chloroquine. FQ completely inhibited the in vivo development of both chloroquine-susceptible and resistant P. vinckei strains and protected mice from lethal infection at a dose of 8.4 mg kg−1 day−1 given for 4 days subcutaneously or orally. This curative effect was 5–20 times more potent than chloroquine, according to the strains' resistance to chloroquine. At this curative dose, no clinical changes were observed in mice up to 14 days after the last administration. Nevertheless, the acute toxicity and lethality of ferrochloroquine seemed to be dependent on gastric surfeit. The FQ security index determined in vitro confirmed that it might be a promising compound.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Received: 12 August 2000 / Accepted: 16 August 2000

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Delhaes, L., Abessolo, H., Biot, C. et al. In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites. Parasitol Res 87, 239–244 (2001). https://doi.org/10.1007/s004360000317

Download citation

Keywords

  • Malaria
  • Growth Inhibition
  • Malaria Parasite
  • Acute Toxicity
  • Chloroquine